Opinion

Video

CGM: Redefining Type 2 Diabetes Management

A panelist discusses how continuous glucose monitoring (CGM) technology can help overcome therapeutic inertia and key barriers to glycemic control in type 2 diabetes (T2D) patients by providing real-time data that enables earlier interventions, supports treatment optimization, and helps managed care organizations justify broader CGM adoption for newly diagnosed patients.

Video content above is prompted by the following:

  • What are the primary barriers to achieving early and consistent glycemic control in T2D patients?
  • How can CGM technology help clinicians address therapeutic inertia in diabetes care?
  • What role does CGM play in reducing the time patients spend with suboptimal glucose management?
  • How can managed care organizations support earlier adoption of CGM in newly diagnosed T2D patients?
Related Videos
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Tom Belmont
Jessica Horwitz, MPH, FNP-C.
4 experts are featured in this series.
4 experts are featured in this series.
2 experts in this video
2 experts in this video
Jessica Horwitz, MPH, FNP-C.
5 experts are featured in this series
5 experts are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo